TGF-b regulates tissue fibrosis: TGF-b promotes fibrosis, whereas bone morphogenetic protein (BMP)-7 is antifibrotic. To demonstrate that (i) left ventricular (LV) remodelling after pressure overload is associated with disequilibrium in the signalling mediated by these cytokines, and (ii) BMP-7 exerts beneficial effects on LV remodelling and reverse remodelling.
Introduction
Aortic stenosis (AS) is an age-related valve disorder; it constitutes the most common adult heart valve disease that requires surgery in the Western world, and it will keep gaining importance due to the progressive increase in life expectancy in our societies. 1 Sustained pressure overload (PO) stress can elicit in the LV from AS patients a harmful remodelling, characterized by concentric hypertrophy and interstitial and perivascular fibrosis, 2 which constitutes a major independent risk factor for heart failure and mortality. 3 Nowadays, the only effective therapy for symptomatic AS patients is the aortic valve replacement. After releasing the biomechanical stress, the LV undergoes a process of reverse remodelling. 4, 5 However, when the LV structural damage is severe, the remodelling process becomes irreversible after surgery, which results in unfavourable short-and long-term outcome of AS patients. 4, 6, 7 The lack of preventive therapies of myocardial remodelling in AS patients highlights need for new effective drugs to delay the progression of LV structural damage before surgery and to improve and accelerate the reverse remodelling after releasing the haemodynamic stress.
The TGF-b superfamily of cytokines is composed, among others, of the prototypic TGF-bs and bone morphogenetic proteins (BMPs). TGF-b and BMP signalling 8 is transmitted by heteromeric complexes of type I [also termed activin-like kinase (ALK)] and type II membrane receptors, with serine/threonine kinase activity. Upon receptor activation, the canonical intracellular signals propagate downstream through the phosphorylation of receptor-activated Smads; p-Smads form complexes with the common partner, Smad4, which translocates to the nucleus to regulate the transcription of target genes. The TGF-b subfamily signals through pSmad2/3, whereas the BMP family signals through pSmad1/5/8 proteins. These signals can be controlled by negative feedback mechanisms via inhibitory Smads. 9, 10 Overproduction of TGF-b contributes to cardiomyocyte hypertrophy and aberrant synthesis and deposition of extracellular matrix (ECM) which characterizes the pathological remodelling of the LV under pressure overload in animal models and in patients suffering from AS or systemic hypertension. 11 -17 TGF-bs promote resident fibroblast proliferation and activation, and stimulate endothelial-to-mesenchymal transition (EMT), increasing the pool of cardiac myofibroblasts. 11, 14 On the other hand, BMP-7 signalling counteracts TGF-b1-induced accumulation of myofibroblasts and ECM production in experimental models of progressive interstitial fibrosis affecting several organs, including the heart. 18, 19 In the present study, we investigated the pathophysiological relevance of an imbalance between TGF-b and BMP-7 signalling in the LV remodelling response in patients suffering from severe AS and in a mouse model of transverse aortic constriction (TAC). The potential for BMP-7 to prevent, slow, or reverse the LV structural damage induced by PO, and to improve the LV reverse remodelling after releasing the haemodynamic stress was assessed in mice.
Methods

Pressure overload studies in mice
The experiments were performed in 12-to 16-week-old littermate female wild-type (C57BL/6) and heterozygous BMP-7-deficient mice (BMP-7 +/2 ) in a C57BL/6 genetic background. 20 The study was approved by the University of Cantabria Institutional Laboratory Animal Care and Use Committee (reference IP0415) and conducted in accordance with the guidelines from directive 2010/63/EU of the European Parliament. All animals received humane care, and all efforts were made to minimize animal suffering.
TAC and release (de-TAC)
Mice were anaesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (5 mg/kg) and subjected to TAC for 4 weeks. 16 In a series of mice, the aortic arch was re-approached, and the constriction was released (de-TAC mice); de-TAC mice were followed up for 1 or 4 weeks. Mice were sacrificed by decapitation under anaesthesia (100 mg/kg ketamine and 5 mg/kg xylazine, i.p.).
Treatments
The Protocols and number of mice per group are shown in the Supplementary material online, Figure S1 . Recombinant murine BMP-7 (rBMP-7, R&D Systems) was administered at the dose of 10 mg/kg/week using osmotic mini-pumps (Alzet 1002) during (i) the complete 4-week TAC period; (ii) the 3rd and 4th weeks following TAC; or (iii) the first week after de-TAC. Minipump implantation was performed during either TAC or de-TAC surgery under ketamine (100 mg/kg) and xylazine (5 mg/kg) anaesthesia or during the echocardiography procedure under anaesthesia with isoflurane (4%). In a series of mice, a monoclonal anti-BMP-7 antibody (clone 164313, R&D Systems) was administered daily (12 mg/day, i.p.) for 7 days starting at the de-TAC surgery.
Echocardiography
Transthoracic echocardiography was performed under sedation with isoflurane (2.5%), with an ultrasound equipment [Vevo-770 (VisualSonics, Toronto, ON, Canada) using a high-resolution transducer centred at 30 MHz]. The operator was blinded to the study groups. Transcoarctational pressure gradients were measured using pulsed-wave Doppler analysis at the distal arch. LV end-diastolic (LVEDd) and end-systolic (LVESd) internal diameters, interventricular septum (IVST), and LV posterior wall (PWT) thicknesses were measured following the recommendations of the American Society of Echocardiography. The degree of geometric concentricity of the remodelled LV was assessed by the relative PWT (rPWT) calculated as: rPWT ¼ PWT/(LVEDd/2). Cardiac mass was estimated using the Devereux's formula. The mitral annular plane systolic excursion (MAPSE) measurements were obtained from four-chamber views using M-mode imaging. The LV ejection fraction (LVEF) and MAPSE were used as surrogates of short axis and longitudinal systolic functions, respectively. Parameters of diastolic LV function (E/e ′ ) were obtained by pulsed-wave mitral inflow analysis and tissue Doppler imaging to obtain the ratio of peak early transmitral flow velocity (E) to peak early myocardial tissue velocity (e ′ ).
Pressure overload studies in patients
The study followed the Declaration of Helsinki guidelines for biomedical research involving human subjects. The institutional ethics and clinical research committee approved the study, and all patients gave written informed consent. The clinical and demographic characteristics of the AS and control groups are shown in Table 1 . The study was performed using LV myocardial intraoperative biopsies obtained from a cohort of 38 patients diagnosed with isolated severe AS and undergoing aortic valve replacement surgery in the University Hospital Marqué s de Valdecilla in Santander, Spain. Patients with aortic or mitral regurgitation greater than mild or with major coronary stenosis .50%, previous cardiac operations, malignancies, or poor renal or hepatic function were deemed ineligible for the study. The control group was a cohort of 26 surgical patients with pathologies (atrial septal defect: n ¼ 13, aortic aneurysm: n ¼ 7, mitral stenosis: n ¼ 4, left atrial myxoma: n ¼ 2) that did not associate LV pressure or volume overload, coronary heart disease or cardiomyopathies. Subepicardial biopsies (4-10 mg) were taken from the LV lateral wall with a Tru-cut needle during the surgical procedure. Samples were all harvested by the same surgeon in a protocolized manner and always from the same location in the margo obtusus of the heart.
Studies in cultured cells
Rat neonatal cardiomyocytes
Cardiomyocytes were obtained from Wistar rats sacrificed by decapitation under sedation with isoflurane (4%) at postnatal day 2-3. The hearts were removed and kept in Ca 2+ /Mg 2+ -free HBBS (Hank's Balanced Salt Solution) medium at 48C. The tissues were minced using a sterile scalpel blade and transferred to a T25 flask containing trypsin (1×, Sigma), type IV collagenase (200 U/mL, Sigma), type I collagenase (0.025 mg/mL, Sigma), and DNase I (0.2 U/mL, Sigma). The flask was settled at 378C for 15 min, and the supernatant was then collected, mixed with HBBS medium, and centrifuged (5 min, 1500 rpm). The cell pellet was re-suspended in DMEM supplemented with 5% FBS and kept at 378C. The harvested cells were plated and incubated for 2 h to allow the attachment and removal of fibroblasts. The cardiomyocytes were plated (300 000 cells per well) in M12 multi-well plates pre-coated with 1% gelatin and cultured in DMEM supplemented with 10% FBS for 48 h. The culture medium was then replaced with Opti-MEM containing TGF-b1 (5 ng/mL), BMP-7 (50 ng/mL), or TGF-b1 (5 ng/mL) plus BMP-7 (50 ng/mL) and incubated for 24 h. The cells were collected and processed for mRNA isolation. Five independent experiments were performed.
Rat H9C2 cardiomyocytes
The H9C2 has been reported to show similar hypertrophic responses than primary neonatal cardiomyocytes. 20 H9C2 cardiomyocytes (ATCC, USA)
were cultured in DMEM supplemented with 10% FBS, 100 U/mL penicillinstreptomycin, at 378C in 5% CO 2 . Cells seeded in 12-well plates (10 5 /well) were cultured for 24 h in Opti-MEM medium and then incubated for 24 h with Opti-MEM containing TGF-b1 (5 ng/mL), BMP-7 (50 nmol/mL), TGF-b1 (5 ng/mL) plus BMP-7 (50 ng/mL), and TGF-b1 plus BMP-7 in combination with the neutralizing antibody anti-BMP-7 (100 ng/mL). The cells were collected and processed for mRNA isolation. Two independent experiments were run in triplicate.
H9C2 cardiomyocytes seeded on glass coverslips were incubated for 24 h with Opti-MEM containing TGF-b1 (5 ng/mL), BMP-7 (50 ng/mL), or TGF-b1 (5 ng/mL) plus BMP-7 (50 ng/mL). After fixation in PFA (3.7% in PBS), cellular actin was stained with FITC-conjugated phalloidin (1% in PBS) for 30 min and with a primary Ab to b-MHC for 60 min. Slides were mounted in Vectashield with DAPI (Vector Labs). A Zeiss Axioplan II microscope was used to acquire the images, and cell area was measured using ImageJ software. Results are reported as the average area of 75 cells per treatment, measured in two different experiments.
NIH-3T3 fibroblasts and dual luciferase reporter assays
NIH-3T3 fibroblasts (ATCC, USA) were cultured in DMEM supplemented with 10% FBS, 100 U/mL penicillin -streptomycin, at 378C in 5% CO 2 . The cells were seeded in 96-well plates (2 × 10 4 /well) and cultured for 24 h in Opti-MEM medium. The cells were co-transfected with pGL3-reporter luciferase vector containing the promoter of Col1A1 (100 ng/well). The DNA transfection reagent was X-tremeGENE 9 (Roche Diagnostics, Germany). The cells were incubated for 24 h with Opti-MEM containing TGF-b1 (5 ng/mL), BMP-7 (50 ng/mL), or TGF-b1 (5 ng/mL) plus BMP-7 (50 ng/mL). Luciferase activity was assessed using a Luciferase w Reporter Assay (Promega) according to the manufacturer's specifications. The assays were performed in three wells on two separate experiments.
mRNA expression
Total RNA was obtained by TRIzol (Invitrogen) extraction. Real-time q-PCR was conducted using specific TaqMan assays (Applied Biosystems) for the following genes: BMP-7, TGF-b1, TGF-b2, TGF-b3, Smad2, Smad3, Smad7, ALK3, ALK6, collagen I (Col I), collagen III (Col III), fibronectin 1 (FN1), b-myosin heavy chain (b-MHC), atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP). Gene expression levels were normalized to ribosomal 18S RNA. Duplicate transcript levels were determined in a minimum of three independent experiments.
Histology
Hearts were fixed in paraformaldehyde (3.7% in PBS) for 48 h and included in paraffin. Four short-axis sections (5 mm) at the level of the papillary muscles (n ¼ 4 mice per experimental condition) were stained using Masson's trichrome. Digital photographs of the full LV sections were captured using a camera (Axiocam MRc5, Zeiss) attached to a Zeiss Axioplan microscope. The fractional area of fibrosis was determined (ImageJ software), and the results were expressed as the blue-stained areas divided by the total LV myocardial area. The minor diameters of cardiomyocytes from the subendocardial region of the posterior wall were measured (25 cells per field, 3 fields per mice, and 4 mice per group). The operator was blinded to the experimental group.
Western blot
Thirty micrograms of protein lysates were electrophoresed on 10% sodium dodecyl sulfate -polyacrylamide gel and transferred onto polyvinylidene difluoride membranes (Bio-Rad, CA, USA). The primary antibodies were goat polyclonal to p-Smad2/3 (Santa Cruz Biotechnology, sc-11769), rabbit polyclonal to p-Smad1/5/8 (cell signalling 9511S); rabbit monoclonal to Smad7 (Abcam, ab90086); mouse monoclonal to BMP7 (R&D, MAB71405); mouse monoclonal to GAPDH (Santa Cruz, sc-32233); and mouse monoclonal to tubulin (Sigma-Aldrich, T5168). After incubation with the appropriate secondary antibodies, proteins were immunodetected with ECL Advance Western Blotting Detection Kit (GE Healthcare) or with infrared fluorescence (Odyssey imager). The results were expressed as optical density of the sample dots normalized to that obtained for GAPDH. Samples from 3 -6 subjects per group were tested in two independent experiments.
Statistics
Data were assessed for normality with the Kolmogorov -Smirnov test. Values were reported as means + S.E.M. Continuous variables were compared using two-tailed Student's t-test or Mann-Whitney U test. Categorical variables were compared with the Fisher's exact test. The influence of genotype, drug treatments, and pressure overload on gene expression was assessed by a two-way ANOVA and on echocardiographic parameters by repeated-measures two-way ANOVA. Bonferroni post-hoc test was used when appropriate. Correlations between mRNA expression levels were performed using Pearson's correlation analysis. Multiple linear regression analysis was used to identify predictors of LV hypertrophy. BMP-7 ventricular remodelling assessment of the regression model in patients was performed with the bootstrapping method with 2000 iterations. Significance levels: *P , 0.05, **P , 0.01, ***P , 0.001. Statistical packages: GraphPad Prism 5.03 and PASW Statistics 18 (SPSS Inc., Chicago, IL, USA).
Results
LV remodelling involves unbalance
between TGF-b1-and BMP-7-mediated signalling in a mouse model of pressure overload TAC caused a stable transcoarctational pressure gradient of ≈50 mmHg during the 4-week follow-up period ( Figure 1A ). Pressure overload resulted in the development of a rapid progressive LV hypertrophy with concentric geometry (increased LVPWT/LVEDr), which was accompanied by LV systolic functional deterioration both in the radial (LVEF) and in the longitudinal axes (MAPSE), and diastolic dysfunction reflected by the rise in the LV filling pressure (E/e ′ ). Four weeks after TAC, mice were subjected to de-TAC surgery, and the morphofunctional echocardiographic evolution was followed for four further weeks ( Figure 1A ). The release of overload stress activated the reverse remodelling process; as a result, LV mass decreased and LVEF, MAPSE, and E/e ′ improved significantly within the first week after de-TAC.
Then, recovery continued at a more gradual rhythm and at 4 weeks, even though LVEF and E/e ′ had already normalized their values, LV mass and MAPSE had not yet returned to baseline figures ( Figure 1A ). LV expression of BMP-7 was significantly reduced in mice subjected to TAC, whereas the expression levels of TGF-b1 and TGF-b2 were up-regulated ( Figure 1B and C ); consequently, the ratios TGF-bs/ BMP-7 increased significantly. The mRNA and protein levels of the inhibitory Smad7 were significantly reduced. Protein levels of p-Smad2/3 increased while those of p-Smad1/5 and Smad7 diminished ( Figure 1D ). Four weeks after releasing the overload stress, the expression levels of BMP-7, the ratios TGF-b1/2 to BMP-7, and the expressions of p-Smad2/ 3, p-Smad1/5/8, and Smad7 recovered the control values ( Figure 1B Linear regression and correlation analysis, performed in the cohorts of TAC and de-TAC mice, show that BMP-7 in the LV correlated significantly and inversely with the mRNA levels of TGF-b1 and TGF-b2 and directly with those of the inhibitory Smad7 ( Figure 2A) . Additionally, the transcript levels of BMP-7 correlated significantly and inversely with the expression of genes encoding ECM elements (Col I, Col III, and FN-1) ( Figure 2B ), consistent with the antifibrogenic properties of this cytokine.
Both the sarcomeric hypertrophic marker b-MHC ( Figure 2B ) and LV mass correlated negatively with BMP-7 ( Figure 2C ), suggesting an antihypertrophy role for BMP-7. Thus, multiple regression analysis ( Figure 2D ) indicated that the myocardial expression of BMP-7 constituted an independent negative predictor of LV posterior wall thickening after TAC, whereas TGF-b2 was a positive predictor. The regression equation was the following:
The adjusted R 2 (0.53; P , 0.001) indicates that 53% of the variance in PWT after TAC can be estimated from this model. Regarding the echocardiographic functional parameters, BMP-7 transcript levels correlated inversely with the mean transcoarctation gradient in TAC mice (R ¼ 0.52**), indicating a relationship between the severity of the constriction and BMP-7 down-regulation. Moreover, the systolic function was positively related to myocardial BMP-7, both in the short-axis (LVEF) and in the long-axis (MAPSE); while the degree of diastolic dysfunction, as reflected by the increase in E/e ′ , was inversely related to BMP-7 mRNA levels ( Figure 2C ).
BMP-7 prevents TGF-b-induced transcriptional activation of the Col1A1 promoter in NIH-3T3 fibroblasts
The stimulation with TGF-b1 (3 ng/mL) of NIH-3T3 fibroblasts, transfected with a full-length promoter of Col1A1-Luc construct, resulted in significant increase of the luciferase activity. BMP-7 (20 ng/mL) significantly repressed transcriptional activation of Col1A1Pro-luc by TGF-b1 (3 ng/mL) ( Figure 3A ).
BMP-7 inhibits TGF-b-induced hypertrophic program in cultured cardiomyocytes
In cultured neonatal rat ventricular cardiomyocytes, the addition of recombinant BMP-7 (50 ng/mL) to the culture medium reduced significantly the overexpression of the hypertrophy markers, ANP, BNP, and b-MHC, induced by TGF-b (5 ng/mL) ( Figure 3B ). The inhibitory effect of BMP-7 on TGF-b-induced overexpression of hypertrophy-related genes in cultured H9C2 cardiomyocytes ( Figure 3C ) was prevented by adding BMP-7 neutralizing Ab (100 ng/mL) to the medium. H9C2 cardiomyocytes seeded on glass coverslips were incubated with TGF-b1, BMP-7, or TGF-b1 plus BMP-7 for 24 h. Cells were stained with FITC-conjugated phalloidin, and cell area was measured using ImageJ. As shown in Figure 3C , TGF-b1 significantly increased the cell area whereas addition of BMP-7 to the medium prevented TGF-b1-induced hypertrophy.
Sustained treatment with recombinant BMP-7 protects the LV from remodelling under biomechanical stress
The usefulness of rBMP7 as pre-emptive treatment against LV remodelling and to stop the ongoing pathological remodelling response was assessed under the following experimental conditions (see Supplementary material online, Figure S1 ): (i) mice treated with a 4-week subcutaneous infusion of rBMP7 starting at the moment of TAC surgery (BMP-7 1 -4wk group); (ii) mice treated with a 2-week subcutaneous infusion rBMP7 starting on Day 15 after TAC surgery when LV hypertrophy and functional deterioration were already taking place (BMP-7 3 -4wk group); and (iii) TAC mice treated with a 4-week subcutaneous infusion of saline as control group. The studies in the literature which analyse the effects of recombinant BMP-7 in mouse models of chronic organ fibrosis reported antifibrotic effects of this cytokine at doses ranging from 1 to 1000 mg/kg/week. 11,21 -24 In a preliminary series, we started treating four TAC mice with 1 mg/kg/week of BMP-7. However, in our hands, the cytokine at such low dose did not induce any significant change in the morpho-functional echocardiographic parameters. Therefore, we increased the dose to 10 mg/kg/week. TAC caused similar transcoarctation pressure gradients ( Figure 4A ) in saline and rBMP7-treated mice at any time of the follow-up, indicating similar degrees of constriction in all groups. The administration of rBMP7 during the 4-week TAC follow-up period diminished PO-induced PW and IVS thickening as well as chamber dilation; as a Figure 1 Aortic constriction in mice induces LV morpho-functional, gene, and protein remodelling changes that regress after deferred constriction release. (A) Echocardiographic morphological and functional changes induced by pressure overload in mice subjected to 4-week TAC (n ¼ 17), and their recovery 4 weeks after releasing the aortic constriction (de-TAC, n ¼ 8). PWT, posterior wall thickness; LVM, LV mass; LVEDd, LV end-diastolic diameter; PWT/LVEDr, posterior wall thickness/LV end-diastolic radius; LVEF, LV ejection fraction; MAPSE, mitral annular plane systolic excursion; E/e ′ , ratio of peak early transmitral flow velocity (E) to peak early myocardial tissue 1 velocity (e ′ ). Data are expressed as mean + SEM. Repeated-measures ANO-VA followed by Bonferroni's test. (B) Myocardial mRNA levels of BMP-7, TGF-b1, and TGF-b2 and the ratios between TGFbs and BMP7 in sham (n ¼ 7), TAC (n ¼ 8), and de-TAC mice (n ¼ 7). ANOVA followed by Bonferroni's test. (C) Myocardial protein levels of BMP-7, TGF-b1, and TGF-b2 determined by western blot in sham, TAC, and de-TAC mice (n ¼ 3 -4 per group). Data are expressed as relative optical density (RD) vs. GAPDH. ANOVA followed by Bonferroni's test. (D) Myocardial protein levels of pSmad1/5/8, pSmad2/3, and Smad7 in sham (n ¼ 4), TAC (n ¼ 5), and de-TAC (n ¼ 4) mice. Data are expressed as relative optical density (RD) vs. GAPDH. Smad7 was determined also by qPCR (sham, n ¼ 6; TAC, n ¼ 6; de-TAC, n ¼ 7). ANOVA followed by Bonferroni's test. Significance levels: *P , 0.05, **P , 0.01, ***P , 0.001. (See detailed statistical analysis in the Supplementary material). RE, relative mRNA expression normalized to 18S. BMP-7 ventricular remodelling result, BMP-7 1 -4wk mice developed a significantly lower degree of LV hypertrophy compared with saline-treated mice. BMP-7 completely prevented TAC-induced systolic dysfunction in the short-axis (LVEF), and the LV systolic function in the long-axis (MAPSE) was significantly less impaired in BMP-7 1 -4wk than in the saline group. The rise in E/e ′ induced by TAC was completely prevented by BMP-7 1 -4wk , which indicates a protection against the development of diastolic dysfunction ( Figure 4A ).
The treatment with rBMP7 during the complete TAC period prevented myocardial overexpression of the remodelling-related genes analysed (TGF-b1, TGF-b2, Col I, Col III, FN1, and b-MHC) ( Figure 5A-F) and attenuated the structural remodelling, as indicated milder histological fibrosis and shorter cardiomyocyte diameters displayed by BMP-7
1 -4wk compared with saline-treated mice ( Figure 5G -I ).
The administration of rBMP7 during the 3rd and 4th weeks of TAC halted the progression of wall thickening, LV hypertrophy, chamber dilation, and systolic and diastolic dysfunctions ( Figure 4A ). The expressions of the remodelling-related genes were lower in BMP-7 3 -4wk than in TAC mice treated with saline ( Figure 5A-F) . At the structural level, the average cardiomyocyte diameter ( Figure 5I ) was significantly smaller, and the LV area occupied by histological fibrosis ( Figure 5G and H ) displayed a decremental trend, but without statistical significance due to the interindividual variability. Overall, our results indicate that down-regulation of BMP-7 during the haemodynamic stress condition was a relevant maladaptive feature of myocardial remodelling and that sustained administration of recombinant BMP-7 prevented pressure overload-induced myocardial hypertrophy, structural damage, and systolic and diastolic dysfunctions. Moreover, when treatment begins once the pathological myocardial remodelling has been established, BMP-7 can stop the progression of the ongoing structural damage and its deleterious functional consequences.
As an approach to ascertain the BMP-7 receptor type involved in the observed effects on gene remodelling and function, linear regression and correlation analysis were performed in a cohort of mice integrated by sham (n ¼ 5), TAC (n ¼ 7), and TAC-BMP-7
1 -4wk TAC (n ¼ 7). The results in Figure 6 show that the relationship of myocardial ALK3 expression levels with all parameters analysed was similar to that of BMP-7. Thus, ALK3 correlated significantly and inversely with the mRNA levels of TGF-b2, Col I, FN1, and b-MHC and directly with Smad7. Also, the transcript levels of ALK3 ( Figure 6C ) correlated inversely with the LVM, directly with the systolic function (LVEF and BMP-7 ventricular remodelling MAPSE) and inversely with the degree of diastolic dysfunction (E/e ′ ).
On the other hand, the expression levels of the other major BMP-7 type I receptor, ALK6, showed no significant relationship with any of the parameters analysed (data not shown). Figure 4B ). No differences between genotypes were evidenced in chamber dimensions, systolic and diastolic functions at baseline. Following TAC, the two genotypes developed similar transcoarctational gradients (wild type: 46.1 + 3.1 mmHg; BMP-7 +/ 2 : 45.6 + 2.5 mmHg).
BMP-7 deficiency potentiates LV
However, BMP-7 +/ 2 mice developed greater levels of LV hypertrophy, either row or indexed, and a more concentric LV geometry than wild-type mice. The systolic (LVEF and MAPSE) and diastolic (E/e ′ ) functions displayed a similar deterioration in both genotypes at any time after TAC ( Figure 4B) . At the structural level ( Figure 7B) , the average diameter of cardiomyocytes was larger in BMP-7 PWT, LV posterior wall thicknesses; PWT/LVEDr, relative PWT to LVED radius; LVMI, LV mass indexed to the naso-anal length; LVEF, LV ejection fraction; MAPSE, mitral annular plane systolic excursion; E/e ′ , ratio of peak early transmitral flow velocity (E) to peak early myocardial tissue velocity (e ′ ). Significance levels: *P , 0.05, **P , 0.01, ***P , 0.001. (See detailed statistical analysis in the Supplementary material online).
than in their wild-type littermates both at baseline and after TAC. The degree of myocardial fibrosis developed was higher in BMP-7 +/2 than in C57BL/6 mice.
LV reverse remodelling in mice is hampered by BMP-7 signalling loss of function and improved by recombinant BMP-7
Four weeks after TAC, a series of mice were subjected to de-TAC surgery. Given that the bulk of the remodelling regression had occurred within the first week after de-TAC ( Figure 1A) , the follow-up of this part of the study was limited to 1 week after de-TAC surgery. We assessed the influence of BMP-7 signalling loss of function on the capability of the heart to reverse the LV remodelling after pressure overload release by de-TAC surgery ( Figure 7) . The subjects of study (see Supplementary material online, Figure S1 ) were the following: (i) TAC-BMP-7 +/2 mice treated with a subcutaneous saline infusion during 7 days after de-TAC; (ii) TAC-WT mice treated with daily injections of a specific monoclonal neutralizing antibody against BMP-7 (BMP-7-Ab, 500 mg/kg/day, 7 days) starting at the moment of de-TAC surgery; and (iii) TAC-WT mice treated with a subcutaneous saline infusion during 7 days after de-TAC. The transcoarctational gradient fell significantly after de-TAC surgery with no differences between groups (de-TAC + saline: 16.9 + 2.3; de-TAC-BMP-7 +/ 2 + saline: 12.5 + 1.2; de-TAC + BMP-7-Ab:
17.6 + 1.1). Both, heterozygous deletion of BMP-7 and BMP-7 neutralization with a BMP-7-Ab during the 7-day de-TAC period hampered the LV morpho-functional recovery after releasing the haemodynamic stress. Regression of LV hypertrophy and the recovery of systolic (LVEF and MAPSE) and diastolic (E/e ′ ) functions were significantly worse in both groups of loss-of-BMP-7 function in comparison with C57BL/6 mice treated with saline ( Figure 7A) . At the structural level ( Figure 7B ), the remaining fibrosis and the average cardiomyocyte diameter after 1-wk de-TAC were significantly higher in BMP-7 +/2 mice and in mice treated with BMP-7-Ab than in wild-type littermates treated with saline. The effect of BMP-7 gain-of-function on reverse remodelling was assessed in a series of wild-type mice treated with rBMP7 during the 7-day de-TAC period ( Figure 7A ). The loss of LV mass during the first de-TAC week was significantly higher in rBMP7-treated than in salinetreated mice. Chamber dilation (LVEDd and LVESd; not shown) BMP-7 ventricular remodelling decreased and systolic function (LVEF and MAPSE) improved to a significantly greater extents with rBMP7 than with saline treatment during the first week after de-TAC. At the structural level ( Figure 7B ), both saline-and rBMP7-treated mice reduced the cardiomyocyte diameter and LV fibrosis area to similar extents.
Translation of the results obtained in the experimental model to the clinical aortic stenosis
The changes induced by pressure overload in the LV expression levels of BMP-7, TGF-b 1, and Smad7 were assessed in a subgroup of 26 pairs of controls and AS patients individually matched by age (within 5 year) and sex. The LV myocardium from AS patients exhibited significantly lower BMP-7 and higher TGF-b1 preoperative expression levels (mRNA and protein) compared with surgical controls ( Figure 8A ). BMP-7 mRNA levels in the AS patients' heart correlated significantly and inversely with the gene expression of TGF-b1 and directly with SMAD7 ( Figure 8B ). As observed in TAC mice, the myocardial gene expression of BMP-7 correlated inversely with the expressions of Col1A1 and Col3A3 ( Figure 8B) , and there was a significant and positive association between BMP-7 expression and the systolic function in the short axis (LVEF). Consistent with an antihypertrophic effect induced by BMP-7, there was an inverse and significant relationship between the cytokine and the LV mass ( Figure 8B ). Stepwise multiple linear regression analysis ( Figure 8C ) evidenced that preoperative BMP-7 was a significant negative predictor of the LV mass, whereas TGF-b1 appeared as a significant positive predictor. The regression equation was the 
Discussion
Our findings in patients with severe AS and in a mouse model of reversible pressure overload raise two important notions: (i) an imbalance between BMP-7 and TGF-b signals could play a major pathogenic role in the maladaptive LV remodelling under pressure overload; and (ii) strategies to enhance the activity of BMP-7 signalling may have putative therapeutic value to attenuate ongoing myocardial hypertrophy and to favour the reverse remodelling after releasing the LV from the haemodynamic load. TGF-b and BMP-7 belong to the same superfamily; however, each of these cytokines exhibit a unique signalling pathway through specific Smad proteins that determine responses that are opposite in each pathway. 8, 18, 19 During the process of pathological remodelling induced by haemodynamic stress, TGF-b is a primary and potent mediator of myocardial fibrosis and hypertrophy both in mice and in humans.
-17
On the other hand, BMP-7 acts as an antifibrotic cytokine in experimental models of pathological organ fibrosis. 18,19,22 -28 Our current results evidenced that pressure overload resulted in biased cellular signalling towards pro-fibrogenic cytokines of the TGF-b family in detriment of BMP-7-mediated signals, both in TAC mice and in AS patients.
We observed LV up-regulation of TGF-bs and down-regulation of R, Pearson's correlation coefficient. RE, relative mRNA expression normalized to 18S. Significance levels: *P , 0.05, **P , 0.01, ***P , 0.001.
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BMP-7 expressions and increased TGF-bs/BMP-7 ratios. Accordingly, the levels of BMP-7 canonical downstream effectors (pSmads1/5/8) were reduced, while those of TGF-b (pSmad2/3) appeared increased.
In the group of pressure-overloaded mice, the balance between TGF-bs and BMP-7 signalling recovered normal values after releasing the haemodynamic stress by de-TAC. Furthermore, myocardial mRNA levels of BMP-7 and those of TGF-bs correlated inversely both in the cohort of operated mice and in AS patients. These results support the existence Figure 7 BMP7 gain and loss of function exerts opposite effects on reverse remodelling after de-TAC in mice. In a series of mice, four weeks after TAC, the aortic constriction was removed (de-TAC) and mice were followed-up for 1 week after de-TAC. C57BL6 mice were treated with saline (n ¼ 8), a BMP7 neutralizing antibody (n ¼ 6, BMP7-Ab) or recombinant BMP7 (n ¼ 5). BMP7 +/2 mice were treated with saline after de-TAC (n ¼ and MAPSE) and inversely to the degree of diastolic dysfunction, reflected by the LV filling pressure (E/e ′ ).
TGF-b, not only plays the above-mentioned key role in the pathogenesis of cardiac fibrosis, but also transduces hypertrophic signals in cardiomyocytes. Cardiomyocyte-targeted canonical (Smads) and non-canonical (TAK1) TGF-b signalling plays a central role in the maladaptive hypertrophic response to sustained pressure overload. 14 Overexpression of TGF-b1 in transgenic mice results in hypertrophic growth of cardiac myocytes accompanied by interstitial and perivascular fibrosis. 33 Studies in vitro also demonstrate that TGF-b directly causes cardiomyocyte hypertrophy and participates in bi-directional regulatory signalling between fibroblasts and cardiomyocytes. 34 LV hypertrophy, although long considered beneficial to preserve fibre shortening in the afterload excess condition, 3 is now recognized as an independent predictor of cardiovascular events as well as of global and cardiovascular mortality. 35 -37 Persistence of LV hypertrophy after aortic valve replacement in AS patients stands as a limiting factor for short-and long-term outcome, 4 -7 whereas LV mass normalization constitutes an independent positive predictor of long-term survival in multivariate analysis.
38
BMP-7 has been reported to be involved in cardiac myogenesis in the chick embryo, 39 and BMP type I and type II receptors and signalling pathways are functional in cardiac myocytes from humans, mice, and rats. 40 Our present results support that during the pressure overload condition, TGF-b overexpression represses BMP-7 production by cardiac cells, as previously reported by Koitabashi et al.
14 In turn, downregulation of BMP-7 results in further strengthening of TGF-b signalling and its ensuing profibrotic/prohypertrophic responses and LV remodelling consequences. TGF-b signalling is modulated by inhibitory Smads. Smad7 binds TGF-b type I receptors and prevents Smad2/3 phosphorylation. 8, 9 In cultured cells, BMP-7 induces Smad7 transcription by interacting with BMP responsive elements in the promoter. 42 Smad7 down-regulation has been reported to potentiate TGF-b-mediated post-infarct fibrosis in rats, 28 whereas recombinant Smad7 protects against angiotensin II-induced hypertensive cardiac remodelling in mice. 43 Our present results show that Smad7 was down-regulated in the LV from AS patients and TAC mice, and its expression normalized after pressure overload release. Moreover, the expression levels of Smad7 in the LV from TAC and de-TAC mice correlated directly with those of BMP-7 and its receptor ALK3. Therefore, we suggest that BMP-7 down-regulation in the pressure overload condition would unleash TGF-b signalling from the Smad7 antagonistic activity. Conversely, the recovery of BMP-7 signals, either by releasing pressure overload or by treating mice with rBMP-7, restrains TGF-b signalling through a mechanism which involves the inhibitory Smad7. Most of the results obtained in the experimental model can be translated into a prevalent clinical condition of pressure overload such as aortic valve stenosis. Thus, the LV from severe AS patients exhibited a lower BMP-7 expression and a higher TGF-b to BMP-7 ratio compared with surgical controls and both transcripts correlated inversely. As observed in TAC mice, in the LV from AS patients, BMP-7 mRNA expression levels correlated inversely with the indexed LV mass, and with Col I and Col III. Also, the systolic function in the short axis (LVEF) was directly related with BMP-7 expression. In fact, the correlation coefficients for patients, with the exception of LV mass, were generally low. Indeed, the regulation of the trophic state of the heart involves multiple, co-ordinated, and redundant signalling circuits that are modified during pathological myocardial remodelling. In this complex biological scenario, pro-and anti-remodelling effectors act in an orchestrated manner and none of them isolatedly explains fully the variance in structural, genetic, and functional LV outcomes.
Overall, our findings strongly suggest that, as observed in TAC mice, during the myocardial remodelling process in humans, lower myocardial expression levels of BMP-7 associate higher TGF-b signalling, more severe structural damage and greater functional echocardiographic abnormalities.
The putative benefit of the activation of BMP-7 signalling to resolve established organ damage has been investigated in rodent models of renal, hepatic, and pulmonary progressive fibrosis. 22 -27 Of note, small peptide agonists of the ALK3 type of BMP-7 receptors have been generated to inhibit kidney inflammation, tissue damage, and fibrosis, 23 and one such peptide, THR-184, is currently being evaluated in clinical studies of renal injury (NIH, ClinicalTrials.gov Identifier: NCT01830920). In our current study, indirect support for a role of such receptors in the cardioprotective effects of BMP-7 was supported by the relationships of myocardial ALK3 with BMP-7, remodelling-related genes, and morpho-functional parameters.
In support of a protective effect against cardiac pathological remodelling, the treatment of TAC mice with exogenous rBMP-7 during the complete follow-up period after TAC prevented the development of myocardial fibrosis, and as a result, the systolic (LVEF and MAPSE) and diastolic (E/e ′ ) functional deteriorations were significantly attenuated compared with saline-treated TAC mice. From a clinical point of view, a major finding of our study is that BMP-7 not only prevented LV remodelling, but also halted its progression when the treatment was started on Day 14th after TAC, when LV hypertrophy and functional deterioration were already taking place. In these animals, the progression of the LV hypertrophy and chamber dilation ceased, the overexpression of ECM-related genes and histological fibrosis tapered, and there was a tendency to improve the systolic function, in both the radial (FEVI) and longitudinal (MAPSE) axes, as well as the diastolic function. BMP-7 signalling also seems to play a relevant positive role in the reverse remodelling process after releasing pressure overload, as evidenced our pharmacological and genetic approaches. Both the treatment of mice with a BMP-7 neutralizing antibody and BMP-7 haploinsufficiency hampered significantly the ability of the LV to recover BMP-7 ventricular remodelling the normal myocardial structure and function after de-TAC. On the contrary, exogenously administered rBMP7 improved some features of the reverse remodelling. Particularly, hypertrophy, chamber dilation, and radial systolic function were significantly improved during the de-TAC recovery period by this treatment.
Reduction of cardiomyocyte volume and LV fibrosis is a usual finding after de-TAC in experimental models of pressure overload. The recovery of the balance between TGF-b-and BMP-7-mediated signals after cessation of haemodynamic overloading could contribute to the reverse remodelling. The correlations between the expression of genes encoding BMP-7 and both sarcomeric and ECM elements support their link with the LV structural changes observed in mice after de-TAC. In line with our present data, Gao et al. 44 in their seminal study described that pressure overload release triggers the reverse remodelling process early after TAC, although various structural, functional, and genetic components display distinct time courses in their reversal towards the baseline levels. Moreover, the time required for recovery of LV structure and function after de-TAC is conditioned by the duration of the preceding pressure overload. Full functional recovery is reached within 6 weeks of de-TAC when TAC is maintained for 4 weeks; on the other hand, after 8 weeks of TAC, restoration of LV structure (particularly the ECM content and organization), chamber geometry, and systolic function require a longer de-TAC period and is less complete. 44 In our study, 4 weeks of de-TAC were not sufficient for the LV to fully reverse hypertrophy, concentric geometry, and MAPSE, a functional parameter strongly linked to myocardial fibrosis. Clinical evidences support the potential for reverse remodelling in patients with chronic heart failure, even rather severe, who have received medical, device-based, or surgical interventions. 45 In AS patients, Krayenbuehl et al. 6 reported that LV fibrous content decreases significantly later than the regression of myocardial cellular hypertrophy after successful valve replacement. Even 6-7 years after valve replacement, LV structural abnormalities compared with the normal myocardium still persist. Such slow myocardial recovery, after releasing the presumably long-standing injury imposed by pressure overload, emphasizes the need for new therapies that improve reversion towards a normal myocardial phenotype. There are a number of limitations in this study. Although TAC in mice is the most widely used experimental model of pressure overload hypertrophy, there are several differences with the clinical scenario (age and sex of the affected subjects, cardiovascular risk factors, pharmacological treatments, coronary artery disease, anatomical level, and time course of the stenosis) that prompt to caution when tempted to directly extrapolate experimental results into clinical practice. On the other hand, pressure overload hypertrophy in humans is subjected to idiosyncratic variation between individuals and influenced by various known factors including age, sex, systemic hypertension, coronary artery disease, diabetes, metabolic syndrome, and obesity. As an example, diabetes mellitus, which affects 22% of our cohort, is an acknowledged confounder in the clinical studies in this field. The diabetic heart undergoes peculiar structural changes that are independently linked to heart failure progression and probably underlie an increased susceptibility to pressure overload. 46 Therefore, the impact of this disease and other confounders in our observations is unavoidable. In summary, our findings support that the imbalance between BMP-7 and TGF-b opposing signals may play an important role in the remodelling response of the heart to the haemodynamic stress. The value of BMP-7 signalling as therapeutic target for the palliative treatment of LV hypertrophy or to improve the reverse remodelling after valve replacement in AS patients deserves further attention.
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